4,300 Shares in Danaher Co. (NYSE:DHR) Purchased by Helios Capital Management PTE. Ltd.

Helios Capital Management PTE. Ltd. bought a new stake in Danaher Co. (NYSE:DHR - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,300 shares of the conglomerate's stock, valued at approximately $995,000. Danaher comprises approximately 0.8% of Helios Capital Management PTE. Ltd.'s portfolio, making the stock its 29th biggest holding.

Several other large investors also recently added to or reduced their stakes in DHR. Sapient Capital LLC bought a new stake in shares of Danaher during the 4th quarter worth about $611,000. Janiczek Wealth Management LLC lifted its holdings in Danaher by 14.0% in the 4th quarter. Janiczek Wealth Management LLC now owns 701 shares of the conglomerate's stock worth $162,000 after purchasing an additional 86 shares during the last quarter. Cerity Partners LLC boosted its position in Danaher by 59.0% during the fourth quarter. Cerity Partners LLC now owns 264,999 shares of the conglomerate's stock worth $61,305,000 after purchasing an additional 98,362 shares during the period. Financial Counselors Inc. grew its holdings in Danaher by 1.0% during the fourth quarter. Financial Counselors Inc. now owns 111,626 shares of the conglomerate's stock valued at $25,824,000 after purchasing an additional 1,077 shares during the last quarter. Finally, Carr Financial Group Corp raised its position in shares of Danaher by 46.8% in the fourth quarter. Carr Financial Group Corp now owns 1,569 shares of the conglomerate's stock valued at $363,000 after purchasing an additional 500 shares during the period. 79.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Raymond James upped their price objective on shares of Danaher from $240.00 to $270.00 and gave the stock an "outperform" rating in a report on Wednesday, January 31st. Wolfe Research began coverage on shares of Danaher in a report on Wednesday, December 13th. They set a "peer perform" rating for the company. StockNews.com lowered Danaher from a "buy" rating to a "hold" rating in a research note on Wednesday, January 31st. Barclays boosted their price objective on Danaher from $240.00 to $260.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Finally, Royal Bank of Canada raised their target price on Danaher from $254.00 to $282.00 and gave the company an "outperform" rating in a report on Wednesday, January 31st. Seven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Danaher has a consensus rating of "Moderate Buy" and a consensus price target of $267.43.

Insider Activity

In related news, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares of the company's stock, valued at $4,898,360.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares of the company's stock, valued at $1,029,891.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Teri List sold 3,289 shares of the company's stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,957 shares of company stock worth $8,265,802. Corporate insiders own 10.90% of the company's stock.

Danaher Stock Performance

Shares of DHR stock traded down $1.87 during mid-day trading on Thursday, reaching $244.00. The stock had a trading volume of 2,051,680 shares, compared to its average volume of 2,694,718. Danaher Co. has a one year low of $182.09 and a one year high of $259.00. The firm has a market cap of $180.69 billion, a PE ratio of 38.18, a P/E/G ratio of 3.71 and a beta of 0.83. The firm's 50 day simple moving average is $249.83 and its 200 day simple moving average is $230.22. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping the consensus estimate of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The firm had revenue of $6.41 billion during the quarter, compared to analysts' expectations of $6.10 billion. During the same period last year, the business earned $2.87 earnings per share. Danaher's quarterly revenue was down 10.2% compared to the same quarter last year. On average, analysts forecast that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. This is an increase from Danaher's previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher's dividend payout ratio (DPR) is presently 16.90%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.